The role of BRAF in the pathogenesis of thyroid carcinoma

被引：26

作者：

Li, Dan-Dan ^{[1
]}

Zhang, Yi-Feng ^{[1
]}

Xu, Hui-Xiong ^{[1
]}

Zhang, Xiao-Ping ^{[2
]}

机构：

[1] Tongji Univ, Peoples Hosp 10, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Shanghai 200072, Peoples R China

[2] Tongji Univ, Inst Med Intervent Engn, Shanghai 200072, Peoples R China

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2015年 / 20卷

基金：

中国国家自然科学基金;

关键词：

BRAF; Thyroid Carcinoma; MAPK; Review; FORCE IMPULSE ELASTOGRAPHY; PHASE-II TRIAL; B-RAF; HUMAN CANCER; EXTRACELLULAR-MATRIX; ONCOGENIC MUTATIONS; KINASE ACTIVATION; SIGNALING PATHWAY; PROTEIN-KINASES; HIGH PREVALENCE;

D O I：

10.2741/4359

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

BRAF is a cytoplasmic serine-threonine protein kinasethat plays a critical role in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by mutation in human cancers. A single amino acid substitution (V600E) accounts for a multitude of human cancers, which causes constitutive kinase activity. In papillary thyroid cancer (PTC) and papillary-derived anaplastic thyroid cancer (ATC), the BRAF(V600E) mutation promotes follicular cell transformation. The BRAF(V600E) mutation could provide valuable prognostic information for thyroid cancer, because this mutation has been correlated with more aggressive and iodine-resistant phenotypes. Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment. Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics. This review will focus on the recent progress in understanding the functions of BRAF, the role of the BRAF mutations in thyroid carcinoma, and the correlation between BRAF mutations and cancer microenvironment.

引用

页码：1068 / 1078

页数：11

共 79 条

[1] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[2] The molecular basis of thyroid epithelial tumorigenesis [J].

Bongarzone, I ;

Pierotti, MA .

TUMORI, 2003, 89 (05) :514-516

[3]

CATLING AD, 1994, J BIOL CHEM, V269, P30014

[4] Mechanisms of regulating the Raf kinase family [J].

Chong, H ;

Vikis, HG ;

Guan, KL .

CELLULAR SIGNALLING, 2003, 15 (05) :463-469

[5] Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer [J].

Ciampi, R ;

Knauf, JA ;

Kerler, R ;

Gandhi, M ;

Zhu, ZW ;

Nikiforova, MN ;

Rabes, HM ;

Fagin, JA ;

Nikiforov, YE .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) :94-101

[6] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study [J].

Cohen, Ezra E. W. ;

Rosen, Lee S. ;

Vokes, Everett E. ;

Kies, Merrill S. ;

Forastiere, Arlene A. ;

Worden, Francis P. ;

Kane, Madeleine A. ;

Sherman, Eric ;

Kim, Sinil ;

Bycott, Paul ;

Tortorici, Michael ;

Shalinsky, David R. ;

Liau, Katherine F. ;

Cohen, Roger B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4708-4713

[7] BRAF mutation in papillary thyroid carcinoma [J].

Cohen, J ;

Xing, MZ ;

Mambo, E ;

Guo, ZM ;

Wu, GG ;

Trink, B ;

Beller, U ;

Westra, WH ;

Ladenson, PW ;

Sidransky, D .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627

[8] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[9] Oncogenic B-Raf mutations: Crystal clear at last [J].

Dhillon, AS ;

Kolch, W .

CANCER CELL, 2004, 5 (04) :303-304

[10] Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis [J].

Eisen, T. ;

Ahmad, T. ;

Flaherty, K. T. ;

Gore, M. ;

Kaye, S. ;

Marais, R. ;

Gibbens, I. ;

Hackett, S. ;

James, M. ;

Schuchter, L. M. ;

Nathanson, K. L. ;

Xia, C. ;

Simantov, R. ;

Schwartz, B. ;

Poulin-Costello, M. ;

O'Dwyer, P. J. ;

Ratain, M. J. .

BRITISH JOURNAL OF CANCER, 2006, 95 (05) :581-586

← 1 2 3 4 5 6 7 8 →